Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications

Molecular Psychiatry

Volumn 17, Issue 10, 2012, Pages 1007-1016

  Tan, H Y ^a   Chen, A G ^a   Chen, Q ^a   Browne, L B ^a   Verchinski, B ^a   Kolachana, B ^a   Zhang, F ^a   Apud, J ^a   Callicott, J H ^a   Mattay, V S ^a   Weinberger, D R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

BDNF; COMT; hippocampus; lithium; schizophrenia; valproate

Indexed keywords

LITHIUM; PEPTIDES AND PROTEINS; PROTEIN AKT1; UNCLASSIFIED DRUG; VALPROIC ACID;

AKT1 GENE; ARTICLE; BDNF GENE; BRAIN FUNCTION; COGNITIVE DEFECT; COMT GENE; CONTROLLED STUDY; GENE; GENETIC EPISTASIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAY MATTER; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MEDIAL TEMPORAL LOBE; MEMORY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; TEMPORAL LOBE;

ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; ECONOMICS, PHARMACEUTICAL; EPISTASIS, GENETIC; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PHOTIC STIMULATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; REACTION TIME; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 84866736870     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.91     Document Type: Article

References (54)

1. Lai WS, Xu B, Westphal KGC, Paterlini M, Olivier B, Pavlidis P et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 2006; 103: 16906-16911.
2. Beaulieu J-M, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007; 28: 166.
3. Lai WS, Xu B, Westphal KGC, Paterlini M, Olivier B, Pavlidis P et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 2006; 103: 16906-16911.
4. Russo SJ, Bolanos CA, Theobald DE, DeCarolis NA, Renthal W, Kumar A et al. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci 2007; 10: 93-99.
5. Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH. New evidence for neurotransmitter influences on brain development. Trends Neurosci 1997; 20: 269.
6. Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapyinduced cell death. Cancer Res 2005; 65: 2070-2075.
7. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry 2005; 58: 446.
8. Thiselton DL, Vladimirov VI, Kuo P-H, McClay J, Wormley B, Fanous A et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry 2007; 63: 449-457.
9. Emamian ES, Hall D, Birnbarum MJ, Karayiogou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia. Nat Genet 2004; 36: 131-137.
10. Norton N, Williams HJ, Dwyer S, Carroll L, Peirce T, Moskvina V et al. Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr Res 2007; 93: 58-65.
11. Tan HY, Nicodemus KK, Chen Q, Li Z, Honea R, Brooke J et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118: 2200-2208.
12. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108: 1158-1163.
13. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology 1993; 9: 67-75.
14. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
15. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825-844.
16. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 2005; 102: 16297-16302.
17. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D0Incecco A, Smit EF et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010; 9: 581-593.
18. Olli PHP, Tiina P, Anu L, Annamari T-H, Tuula K, Paul T et al. Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 683-692.
19. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/b-Arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-273.
20. Johnson-Farley NN, Travkina T, Cowen DS. Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J Pharmacol Exp Ther 2006; 316: 1062-1069.
21. Spencer JL, Waters EM, Milner TA, Lee FS, McEwen BS. BDNF variant Val66Met interacts with estrous cycle in the control of hippocampal function. Proc Natl Acad Sci USA 2010; 107: 4395-4400.
22. Yoshii A, Constantine-Paton M. BDNF induces transport of PSD-to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat Neurosci 2007; 10: 702
23. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592.
24. Glorioso C, Sabatini M, Unger T, Hashimoto T, Monteggia LM, Lewis DA et al. Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. Mol Psychiatry 2006; 11: 633-648.
25. Huang YY, Kandel ER. D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci USA 1995; 92: 2446-2450.
26. Lisman JE, Grace AA. The Hippocampal-VTA Loop: controlling the entry of information into long-term memory. Neuron 2005; 46: 703.
27. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257.
28. Chen Z-Y, Jing D, Bath KG, Ieraci A, Khan T, Siao C-J et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-143.
29. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al. Functional analysis of genetic variation in catechol-Omethyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807-821.
30. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
31. Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with 11C NNC112 and PET. Mol Psychiatry 2008; 13: 821-827.
32. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96: 8745.
33. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158.
34. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23: 6690-6694.
35. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004; 24: 10099-10102.
36. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907.
37. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330.
38. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional imaging using the false discovery rate. Neuroimage 2002; 15: 870-878.
39. Ji Y, Pang PT, Feng L, Lu B. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci 2005; 8: 164.
40. Jay TM. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003; 69: 375-390.
41. Schott BH, Seidenbecher CI, Fenker DB, Lauer CJ, Bunzeck N, Bernstein H-G et al. The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J Neurosci 2006; 26: 1407-1417.
42. Bertolino A, Di Giorgio A, Blasi G, Sambataro F, Caforio G, Sinibaldi L et al. Epistasis between dopamine regulating genes identifies a nonlinear response of the human hippocampus during memory tasks. Biol Psychiatry 2008; 64: 226-234.
43. Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, Fazio L et al. Prefrontal-hippocampal coupling during memory processing is modulated by COMT Val158Met genotype. Biol Psychiatry 2006; 60: 1250-1258.
44. Krach S, Jansen A, Krug A, Markov V, Thimm M, Sheldrick AJ et al. COMT genotype and its role on hippocampal-prefrontal regions in declarative memory. Neuroimage 2010; 53: 978-984.
45. Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MAM, Nicoletti M et al. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology 2007; 33: 1229.
46. Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 2010; 327: 863-866.
47. Rossato JI, Bevilaqua LRM, Izquierdo I, Medina JH, Cammarota M. Dopamine controls persistence of long-term memory storage. Science 2009; 325: 1017-1020.
48. Skelley SL, Goldberg TE, Egan MF, Weinberger DR, Gold JM. Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia. Schizophr Res 2008; 105: 78.
49. Sherren N, Pappas BA. Selective acetylcholine and dopamine lesions in neonatal rats produce distinct patterns of cortical dendritic atrophy in adulthood. Neuroscience 2005; 136: 445-456.
50. Shao H, Burrage LC, Sinasac DS, Hill AE, Ernest SR, O'Brien W et al. Genetic architecture of complex traits: large phenotypic effects and pervasive epistasis. Proc Natl Acad Sci USA 2008; 105: 19910-19914.
51. Gerke J, Lorenz K, Cohen B. Genetic interactions between transcription factors cause natural variation in yeast. Science 2009; 323: 498-501.
52. Waddington CH. Canalization of development and the inheritance of acquired characters. Nature 1942; 150: 563.
53. Moore JH, Williams SM. Epistasis and its implications for personal genetics. Am J Human Genet 2009; 85: 309.
54. Fountoulakis KN, Vieta E, Bouras C, Notaridis G, Giannakopoulos P, Kaprinis G et al. A systematic review of existing data on longterm lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol 2008; 11: 269.